## Abstract To date, there has been little examination of the problems associated with conducting economic evaluation for interventions designed to contain antimicrobial resistance. There are two quite different types of intervention aimed at containing antimicrobial resistance: interventions which
Superbugs: Should antimicrobial resistance be included as a cost in economic evaluation?
✍ Scribed by Joanna Coast; Richard D. Smith; Michael R. Millar
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 940 KB
- Volume
- 5
- Category
- Article
- ISSN
- 1057-9230
No coin nor oath required. For personal study only.
✦ Synopsis
This paper argues that increasing resistance to antimicrobials is an important social externality that has not been captured at the level of economic appraisal. The paper explicitly considers reasons why the externality of antimicrobial resistance has not generally been included as a cost in economic evaluations comparing management strategies for infectious diseases. Four reasons are considered: first, that the absolute cost of antimicrobial resistance is too small to be worth including; second, that there is an implicit discounting of the costs of antimicrobial resistance on the basis of time preference which makes the cost too small to be worth including; third, that there is an implicit discounting of the costs of antimicrobial resistance on the basis of uncertainty which makes the cost too small to be worth including; and fourth, that the costs are too difficult to measure. Although there does not appear to be methodological justification for excluding the costs of antimicrobial resistance, it Seems likely that, because of the practical difficulties associated with measuring these costs, they will continue to be ignored. The paper concludes with a discussion of the applicability of standard policy responses used to deal with externalities in other areas of welfare economics.
📜 SIMILAR VOLUMES
## Abstract Survivor costs are those costs associated with a treatment because it extends the patient's life. A controversy exists regarding whether survivor consumption costs should be included in cost–utility analyses. The present paper uses this controversy to motivate a general reexamination of